Search - tctmd.com

Displaying 1 - 6 of 6

Sort: Relevancy | Date

Presentation EuroPCR 2025

Complete or culprit-only revascularisation in STEMI: 10-year outcome of DANAMI-3-PRIMULTI

Presenter: Thomas Engstrøm

May 22, 2025

Presentation EuroPCR 2024

Prognostic value of MRR in STEMI: a pooled analysis of individual patient data

Presenter: Mohamed El Farissi

May 14, 2024

Presentation EuroPCR 2017

Prasugrel, Ticagrelor and Clopidogrel in PPCI for STEMI: An Analysis of Comparative Clinical Outcomes from the UK BCIS National Registry

Presenter: Mamas A. Mamas

May 22, 2017

Presentation EuroPCR 2015

Multivessel Coronary Disease Diagnosed at the Time of Primary PCI for STEMI: Complete Revascularization Versus Conservative Strategy - PRAGUE 13 Trial

Presenter: Ota Hlinomaz

May 19, 2015

$Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial$

Presentation EuroPCR 2014

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Presenter: Uwe Zeymer

May 21, 2014

Presentation EuroPCR 2012

APPOSITION III: Evaluation of the STENTYS self-apposing bare and drug-eluting stent in 1000 STEMI patients in a real-life setting: in-hospital and 30-day outcomes

Presenter: 166648|giovanni amoroso

May 18, 2012

Advertisement

Complete or culprit-only revascularisation in STEMI: 10-year outcome of DANAMI-3-PRIMULTI

Prognostic value of MRR in STEMI: a pooled analysis of individual patient data

Prasugrel, Ticagrelor and Clopidogrel in PPCI for STEMI: An Analysis of Comparative Clinical Outcomes from the UK BCIS National Registry

Multivessel Coronary Disease Diagnosed at the Time of Primary PCI for STEMI: Complete Revascularization Versus Conservative Strategy - PRAGUE 13 Trial

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

APPOSITION III: Evaluation of the STENTYS self-apposing bare and drug-eluting stent in 1000 STEMI patients in a real-life setting: in-hospital and 30-day outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content